

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
22 May 2008 (22.05.2008)

PCT

(10) International Publication Number  
**WO 2008/060356 A3**

(51) **International Patent Classification:**  
**A61K 47148 (2006.01) C12N 15/861 (2006.01)**  
**A61K 48/00 (2006.01)**

(21) **International Application Number:**  
**PCT/US2007/020931**

(22) **International Filing Date:**  
28 September 2007 (28.09.2007)

(25) **Filing Language:** English

(26) **Publication Language:** English

(30) **Priority Data:**  
60/848,614 29 September 2006 (29.09.2006) US

(71) **Applicant (for all designated States except US):** **CANJI, INC.** [US/US]; 901 California Avenue, Palo Alto, CA 94304 (US).

(71) **Applicant and**

(72) **Inventor: LAFACE, Drake, M.** [US/US]; 648 Terrace Avenue, Half Moon Bay, CA 94019 (US).

(72) **Inventor; and**

(75) **Inventor/Applicant (for US only):** **TSAI, Van, T.** [US/US]; 12892 Ralston Circle, San Diego, CA 92130 (US).

(74) **Agent: GRUPPI, Carol, M.;** Schering Corporation, 2000 Galloping Hill Road, Patent Dept K-6-1 1990, Kenilworth, NJ 07033 (US).

(81) **Designated States (unless otherwise indicated, for every kind of national protection available):** AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

(84) **Designated States (unless otherwise indicated, for every kind of regional protection available):** ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) **Date of publication of the international search report:**  
24 July 2008

(54) **Title:** METHODS AND COMPOSITIONS FOR GENE THERAPY

(57) **Abstract:** The present invention relates to improved methods for gene therapy, particularly gene therapy using PEGylated adenovirus. In particular the invention provides methods and compositions for mitigating the adverse effects associated with systemic administration of recombinant adenovirus for gene therapy.



**WO 2008/060356 A3**

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2007/020931

<b>A. CLASSIFICATION OF SUBJECT MATTER</b> INV.    A61K47/48                    A61K48/00                    C12N15/861		
According to International Patent Classification (IPC) or to both national classification and IPC		
<b>B. REIDS SEARCHED</b>		
Minimum documentation searched (classification system followed by classification symbols) A61K   C12N		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical search terms used) <b>EPO-Internal , BIOSIS, CHEM ABS Data</b>		
<b>C. DOCUMENTS CONSIDERED TO BE RELEVANT</b>		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	WO 00/11202 A (GENZYME CORP [US]; WADSWORTH SAMUEL C [US]; RIORDAN CATHERINE E 0 [US]) 2 March 2000 (2000-03-02) page 5 , line 10 page 15, line 13 - line 16 page 21 - page 22 examples; tables 1,2 -----	1-14
X	CROYLE M A ET AL: "PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile." GENE THERAPY APR 2005, vol. 12, no. 7 , April 2005 (2005-04), pages 579-587, XP002479207 ISSN: 0969-7128 the whole document -----	1-14
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C	<input checked="" type="checkbox"/> See patent family annex	
* Special categories of cited documents		
'A' document defining the general state of the art which is not considered to be of particular relevance	'1T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	
'E' earlier document but published on or after the international filing date	'1X' document of particular relevance, the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	
'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	'*Y' document of particular relevance, the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	
'O' document referring to an oral disclosure, use, exhibition or other means	'&' document member of the same patent family	
'P' document published prior to the international filing date but later than the priority date claimed		
Date of the actual completion of the international search  <p style="text-align: center;">6 May 2008</p>	Date of mailing of the international search report  <p style="text-align: center;">26/05/2008</p>	
Name and mailing address of the ISA/ European Patent Office, P B 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel (+31-70) 340-2040, Tx 31 651 epo nl, Fax (+31-70) 340-3016	Authorized officer  <p style="text-align: center;">Armandol a, Elena</p>	

INTERNATIONAL SEARCH REPORT

International application No  
PCT/US2007/020931

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DE GEEST BART ET AL: "Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methyl prednisolone." HUMAN GENE THERAPY DEC 2005, vol. 16, no. 12, December 2005 (2005-12), pages 1439-1451, XP002479208 ISSN: 1043-0342 the whole document</p> <p>-----</p>	1-14
X	<p>MOK H ET AL: "Evaluation of polyethylene glycol modification of first-generation and helper-dependent adenoviral vectors to reduce innate immune responses" MOLECULAR THERAPY, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 11, no. 1, January 2005 (2005-01), pages 66-79, XP004672528 ISSN: 1525-0016 page 67, right-hand column, last paragraph</p> <p>-----</p>	1-14
P,X	<p>LEE SEOJU ET AL: "Investigations of PEGylated recombinant adenovirus, using fluorescein-labeled polyethylene glycol" HUMAN GENE THERAPY, MARY ANN LIEBERT, NEW YORK ,NY, US, vol. 18, no. 3, March 2007 (2007-03), pages 286-300, XP002446936 ISSN: 1043-0342 the whole document</p> <p>-----</p>	1-14
P,X	<p>WO 2007/062207 A (SCHERING CORP [US]; LEE SEOJU [US]; VELLEKAMP GARY J [US]) 31 May 2007 (2007-05-31) page 17, line 5 - line 8 ; example 13</p> <p>-----</p>	1-14

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2007/020931

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0011202	A	02-03-2000	AU 5685799 A	14-03-2000
			CA 2341516 A1	02-03-2000
			EP 1108048 A1	20-06-2001
			JP 2002523054 T	30-07-2002
-----				
WO 2007062207	A	31-05-2007	NONE	
-----				